Darzalex Surpasses Stelara As J&J’s Best-Selling Drug

Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.

Johnson & Johnson reported first quarter financial results • Source: Shutterstock

More from Earnings

More from Business